Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Oramed Pharmaceuticals  / Equity Bottom-Up

<ul><li>The company's discussions with the FDA progress as ORMP plans to launch a Phase 3 oral insulin trial in the U.S. under a differentiated protocol aligned with the positive data from specific patient subgroups in a prior Phase 3 study of ORMD 0801.</li><li>ORMP hopes to leverage its analysis of the patient subgroups' responses in order to fine-tune its development efforts under a revised protocol to advance its oral insulin therapy in diabetes management.</li><li>ORMP is also continuing discussions with Hefei Tianhui Biotech Co., Ltd. (HTIT) regarding their strategic JV to leverage their respective strengths and combined capabilities and technologies.</li></ul>

The company's discussions with the FDA progress as ORMP plans to launch a Phase 3 oral insulin trial in the U.S. under a differentiated protocol aligned with the positive data from specific patient subgroups in a prior Phase 3 study of ORMD 0801.ORMP hopes to leverage its analysis of the patient subgroups' responses in order to fine-tune its development efforts under a revised protocol to advance its oral insulin therapy in diabetes management.ORMP is also continuing discussions with Hefei Tianhui Biotech Co., Ltd. (HTIT) regarding their strategic JV to leverage their respective strengths and combined capabilities and technologies.

ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks

<ul><li>Having completed an analysis of data from its terminated ORA-D-013-1 Phase 3 trial, Oramed is optimistic about prospects for ORMD-0801, particularly for certain subpopulations of patients with specific parameters that match those of study participants who responded well to oral insulin.</li><li>ORMP has initiated discussions with the FDA and plans to launch a Phase 3 oral insulin trial in the U.S. under a differentiated protocol aligned with the positive data.</li><li>Separately, a recent licensing agreement with Genomma Lab could provide attractive royalty revenue, if Genomma can commercialize an OTC hemorrhoids treatment & other products for which ORMP had acquired the rights.</li></ul>

Having completed an analysis of data from its terminated ORA-D-013-1 Phase 3 trial, Oramed is optimistic about prospects for ORMD-0801, particularly for certain subpopulations of patients with specific parameters that match those of study participants who responded well to oral insulin.ORMP has initiated discussions with the FDA and plans to launch a Phase 3 oral insulin trial in the U.S. under a differentiated protocol aligned with the positive data.Separately, a recent licensing agreement with Genomma Lab could provide attractive royalty revenue, if Genomma can commercialize an OTC hemorrhoids treatment & other products for which ORMP had acquired the rights.

ORMP: Moving Oral Delivery Platform Forward, + Potential to Generate Royalties

Israel

Oramed Pharmaceuticals, Inc. is a pharmaceutical company focused on the development of oral delivery solution. The Company is developing orally ingestible insulin capsules for the treatment diabetes as well as delivery solutions for other drugs and vaccines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oramed Pharmaceuticals (ORMP US)

ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks

The company's discussions with the FDA progress as ORMP plans to launch a Phase 3 oral insulin trial in the U.S. under a differentiated protocol...

Zacks Small Cap Research

ORMP: Moving Oral Delivery Platform Forward, + Potential to Generate Royalties

Having completed an analysis of data from its terminated ORA-D-013-1 Phase 3 trial, Oramed is optimistic about prospects for ORMD-0801,...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)